Tag: filing

METTAWA, Ill., July 09, 2025 (GLOBE NEWSWIRE) -- Brunswick Corporation (NYSE: BC) will release its 2025 second quarter financial results on Thursday, July 24, 2025 before the market opens by way of an advisory release, notifying the public that the complete and full-text results will be available on the Company’s website at https://ir.brunswick.com.  The results will also be available on the SEC’s website with the Form 8-K filing of the release at http://goo.gl/wJQN1.   

Outcome of Regenerative Medicine Advanced Therapy (RMAT) meeting provides clear regulatory pathway to approval in a continuous Phase 1 / 2 / 3 study, avoiding the requirement for an additional registrational study and accelerating time to potential approval

“We have a team of people and outside counsel working around the clock to assess our options” - Shareholder Coalition

WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 22,222,223 shares of its common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Cogent has granted the underwriters a 30-day option to purchase up to an additional 3,333,333 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Cogent. The offering is expected to close on or about July 10, 2025, subject to the satisfaction of customary closing conditions.

Not for dissemination in the United States of America

WALTHAM, Mass. and BOULDER, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced an underwritten public offering of $150 million of its shares of common stock. In addition, Cogent intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its shares of common stock on the same terms and conditions. All of the securities in the offering are being offered by Cogent. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

BOCA RATON, FL, July 08, 2025 (GLOBE NEWSWIRE) -- DeFi Development Corp. (Nasdaq: DFDV) (the “Company”) the first public company with a treasury strategy built to accumulate and compound Solana (“SOL”), announced today the purchase of 47,272 Solana (“SOL”) at an average purchase price of $149.09 and valued at approximately $7.03 million. Following the transaction, DeFi Development Corp. now holds a total of approximately 690,420 SOL and SOL equivalents, valued at approximately $102.7 million, inclusive of staking rewards. The latest purchase marks a +64.1% increase in the Company’s SOL and SOL equivalent holdings compared to 420,690 SOL held 60 days prior.

SAN FRANCISCO, July 08, 2025 (GLOBE NEWSWIRE) -- After hours on June 25, 2025, Connecticut-based private equity firm Compass Diversified (NYSE: CODI) filed a report with the SEC warning investors not to rely on previously issued financial statements for its fiscal years ended- and interim periods within- December 31, 2022 and 2023, citing an expanded scope of previously disclosed accounting irregularities.

Not for distribution to U.S. News wire services or dissemination in the U.S.